WO2001080921A2 - Native protein mimetic fibers, fiber networks and fabrics for medical use - Google Patents
Native protein mimetic fibers, fiber networks and fabrics for medical use Download PDFInfo
- Publication number
- WO2001080921A2 WO2001080921A2 PCT/US2001/012918 US0112918W WO0180921A2 WO 2001080921 A2 WO2001080921 A2 WO 2001080921A2 US 0112918 W US0112918 W US 0112918W WO 0180921 A2 WO0180921 A2 WO 0180921A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fiber
- fibers
- elastin
- nonwoven fabric
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F4/00—Monocomponent artificial filaments or the like of proteins; Manufacture thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/222—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0076—Chemical modification of the substrate
- A61L33/0082—Chemical modification of the substrate by reacting with an organic compound other than heparin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Definitions
- the present invention relates to fibers, fiber networks and fabrics formed, at least in part, from synthetic elastm-mimetic proteins, functionalized elastin mimetic proteins including methacrylate-, vinyl- or acrylate-modified elastin-mimetic proteins, functionalized collagen such as aery late-, vinyl- or or methacrylate modified collagen, functionalized gelatin modified in a similar manner to the foregoing proteins, collagen fibers, gelatin fibers, crosslinked collagen, gelatin or elastin mimetic fibers, and fiber networks and fabrics made using these materials.
- Atherosclerosis is a serious cause of morbidity and death despite advances in preventive measures and pharmacological therapeutics. Nearly 700,000 vascular surgical procedures are performed annually in the United States, along with several hundred thousand peripheral and coronary angioplasties. Prosthetic bypass grafts and, more recently, arterial stents and other endovascular prostheses have been utilized in association with these reconstructive procedures . Although large diameter vascular grafts ( ⁇ 6 mm internal diameter) have been successfully developed from polymers such as polytetrafluoroethylene and polyethylene terephthalate, the fabrication of a durable small diameter prostheses ( ⁇ 6 mm internal diameter) remains unsolved.
- prosthetic bypass grafting can be performed in the infrainguinal position with reasonable short-term success, within 5 five years 30% to 60% of these grafts will fail. 5 Likewise, restenosis and/or occlusion occurs in as many as 50 % of all patients within 6 months of stent placement, depending upon the site and the extent of the disease.
- Grafts and stents have been coated with albumin, heparin, or prostacyclin analogues, which inhibit the clotting cascade and platelet reactivity, or with relatively inert materials, such as polyethylene oxide.
- An alternate approach has been to design arterial substitutes on the basis of tissue engineering principles in which a vessel construct is created using cultured endothelial cells, smooth muscle cells (SMC), and fibroblasts, which are
- organ substitutes including, without limitation, blood vessels, heart valves, ligaments,
- the present invention pNrovides biologically compatible protein fibers, fiber networks, fabrics and crosslinked fibers for use in medical and veterinary applications. These materials
- the present materials are characterized by resilience, flexibility, extensibility, tensile strength, mechanical strength and ability to recover shape after distortion, similar to that of native proteins in biological materials.
- the present materials especially those which comprise crosslinked elastin, crosslinked elastin mimetic protein, crosslinked collagen and/or crosslinked gelatin, are especially useful in the medical or veterinary area because of the similarity of the physical
- the present invention provides elastin mimetic proteins and crosslinked materials formed into fibers, fiber networks, fabrics and tubing.
- the fibers can be in the form of thin
- These materials can optionally include at least one additional material which is fiber-forming but which does not include functional groups which can mediate crosslinking such as poly(ethylene oxide) which provides some physical strength to the material and again, optionally, a biologically
- active material such as a therapeutic protein or other pharmacologically compound.
- a 5 polysaccharide can also be incorporated.
- the fiber morphology and physical properties are affected by the PEO molecular weight as well as by the relative amount of PEO in the fiber forming solution.
- the PEO dissolves relatively slowly under physiological conditions, which can provide for release of the additional material(s).
- Anti-inflammatory agents and/or growth factors which stimulate wound healing or tissue repair and antitumor agents are but a few of
- an initiator of crosslinkage e.g., a photoinitiator
- a photoinitiator can be incorporated into the solution from which the
- the present invention further provides improved prosthetic materials for medical and veterinary use. These materials are formed of functionally modified elastin mimetic fibers which have been crosslinked using photoinitiators (i.e., under relatively mild conditions with
- Prosthetic materials can include, without limitation, tubing for vascular prostheses, ureters, esophagus, bladder, intestine, heart planar materials for use in reinforcing injured tissues (cartilage, tendons, heart valves, heart muscle, bladder, esophagus, ligament, stomach, among others) and for use as topical applies materials for promoting wound healing 5 after injury or in facilitating healing of surgical incisions (including without limitation intestinal anastomeses or lung biopsy) or remediation of hernias.
- Crosslinking can be effected after casting each protein layer or crosslinking can take place after a multilayer material has been produced.
- hydrophilic polysaccharides and/or glycopolymers can be incorporated to reduce adhesion formation after surgical intervention
- hybrid elastin/collagen materials which can be formed by depositing alternating layers of elastin or an elastin mimetic protein, either as protein fibers or as cast films of native protein and/or elastin mimetic protein and collagen
- Nonwoven fabrics are especially useful products of the present 5 invention.
- the functionally modified elastin or elastin mimetic protein and/or collagen can be crosslinked once formed into nonwoven fabrics for improved stability, resistance to dissolution and improved physical properties.
- An advantageous aspect of the present invention is a lamellar repeat of an elastin mimetic layer sandwiched between collagen layers .
- the nonwoven fabric of this aspect of the invention can have from one lamellar repeat up to about ten
- each lamellar repeat layer affects the ultimate physical properties of the product.
- the living cells can be at least one of, but not limited to endothelial cells, smooth muscle cells, fibroblasts, stem cells, chondrocytes, osteoblasts or a human or animal cell which has been genetically engineered to produce a protein of interest.
- the protein of interest can be a growth factor which could promote wound healing, or a peptide hormone such as insulin in the context of an artificial organ, or an antiangiogenic protein to be used in an antitumor
- the living cells can be incorporated between lamellar repeat units , and the cells can be deposited by techniques including, but not limited to, electrodeposition and sedimentation.
- the materials of the present invention can be used in the form of conduits, or planar '5 sheets or they can be formed into other shapes by rolling to form hollow tubing or by sequential deposition onto a rotating mandrel or other forms or molds.
- Figs 1A-1B show the V start and V stop for various solution concentrations (Fig. 1A) and i0 corresponding viscosities (Fig. IB) of elastin-mimetic peptide aqueous solutions.
- Figs. 2A-2D present SEM micrographs of elastin-mimetic peptide fibers spun from 5 wt% solution at 50 ⁇ l/wl (Fig. 2A), 100 l/ml (Fig. 2B), 150 ⁇ l/ml (Fig. 2C), 200 ⁇ l/ml (Fig. 2D) flow rate.
- 5 Figs . 3 A-3D present SEM micrographs of elastm-mimetic peptide fibers spun from 10 wt% solution at 50 ⁇ llml (Fig. 3A), 100 ⁇ l/ml (Fig. 3B), 150 ⁇ l/ml (Fig. 3C), 200 ⁇ l/ml (Fig. 3D) flow rate.
- Figs. 4A-4D present SEM micrographs of elastin-mimetic peptide fibers spun from 15 0 wt% solution at 50 ⁇ l/ml (Fig. 4A), 100 ⁇ l/ml (Fig. 4B), 150 ⁇ l/ml (Fig. 4C), 200 ⁇ l/ml (Fig. 4D) flow rate.
- Figs. 5A-5D present SEM micrographs of elastin-mimetic peptide fibers spun from 20 wt% solution at 50 ⁇ l/ml (Fig. 5A), 100 ⁇ l/ml (Fig. 53B), 150 ⁇ l/ml (Fig. 53C), 200 ⁇ l/ml 5 (Fig. 5D) flow rate.
- Figs. 6A-6D are high resolution SEM (Figs.6 A and 6B) and TEM (Figs. 6C and 6D) micrographs of elastin-mimetic peptide fibers spun from a 20% wt% solution at 100 ⁇ l/ml flow rate, which demonstrate a twisted ribbon-like morphology. ,0
- Figs. 7A-7B are SEM micrographs (Figs. 7 A and 7B) of a non- woven fabric spun from a 15% wt. solution of elastin-mimetic peptide at 150 ⁇ l/ml.
- Fig. 8 illustrates fiber diameter distribution within a non- woven fabric spun from a 15 '.5 wt% solution of elastin-mimetic peptide at 150 ⁇ l/ml.
- Fig. 9 shows distribution of fiber orientation within a non- woven fabric spun from a 15 wt% solution of elastin-mimetic peptide at 150 ⁇ l/ml.
- i0 Fig. 10 is a representative uniaxial stress-strain curve for drying a non-woven fabric of elastm-mimetic peptide fibers.
- Figs. 11A shows H NMR spectra of elastin and elastin methacrylamide measured in
- Fig. 12 shows H NMR spectra of elastin and AME.
- the DOF of AME's is provided in the brackets.
- the expanded portion of the spectra between 2.6 and 3.1 ppm.
- the DOF can be computed from the integrated intensities of the H° and H d peaks.
- Fig. 13 shows temperature-dependent turbidimetry data for elastin and acrylate- modified elastin with different degrees of functionalization.
- the inverse transition temperature (T decreases with increase in the degree of functionalization (DOF).
- DOF dictates the temperature (processing window) at which fibers can be formed from aqueous solutions.
- the temperature window to the left of T t is amenable for fiber formation.
- Fibers in a variety of diameter ranges are produced (typically from 300 nm - 2 ⁇ m).
- Fig. 16 shows 13 C CP/MAS/TOSS spectra of elastin-mimetic polypentapeptide, methacrylate-modified elastin and crosslinked elastin recorded at room temperature (23 °C).
- Disappearance of the peaks C a and C b in the spectrum for the crosslinked material indicate complete crosslinking after exposure either to UV at 365 nm or visible light.
- the peaks labeled "*" are from the photoinitiator (Irgacure 2959 * ) employed for crosslinking.
- Fig. 17 illustrates degree of crosslinking of AME(88) determined by 13 C solid-state NMR as a function of irradiation time. Data presented as mean + standard deviation.
- Fig. 18(A) shows a stress-strain curve of crosslinked and uncrosslinked fabric samples of elastin methacrylamide in the dry state. Crosslinking increases both tensile strength and modulus of the sample.
- Fig. 18B shows stress-strain curves of dry and hydrated (O) crosslinked AME(65) fabric samples of elastin methacrylamide measured at a strain rate of 1 mm/min at room temperature.
- Figs. 19A-19D are SEM micrographs of collagen-PEO (1:1) fibers spun from 2wt% acid solution at a flow rate of 100 ⁇ L/min and at different NaCl concentrations: Fig. 19 A,
- Fig. 19B 15mM NaCl, 10 kX magnification
- Fig. 19B 25mM NaCl, 5kX magnification
- Fig. 19C 34mM NaCl, 2 kX magnification
- Fig. 19D 68mM NaCl, 5 kX magnification.
- Figs. 20A-20D are SEM micrographs of collagen-PEO (1 : 1 (w/w), 34 mM NaCl) fibers spun from 2wt% acid solution at different flow rates ( ⁇ L/min): Fig. 20 A, 25; Fig. 20B,
- Fig. 21 shows 13 C MAS spectra of collagen, PEO and a 1:2 collagen-PEO blended fabric.
- the CP spectrum of the blend appears to be a simple superposition of the CP spectrum of PEO (*) and collagen (C).
- the DP spectrum of the blend shows that PEO is highly mobile in the sample when compared to collagen at the measuring temperature (24 °C).
- Fig. 22 A shows the H NMR spectrum of 1:2 collagen-PEO fabric is shown before and after the application of the dipolar filter.
- the dipolar filter eliminates the broad component of the spectrum and retains the narrow component.
- Fig. 22B shows the 13 C CP/MAS/TOSS spectra before and after application of the dipolar filter. After selection, only the PEO resonance is retained demonstrating that effective selection of mobile component has been achieved using the dipolar filter.
- Fig. 23 provides spin diffusion data for 1:1 and 1:2 collagen-PEO fabrics. The initial portion of the curve, corresponding to times less than 9 ms, is shown in the inset. The data illustrates the presence of an interface for a 1 : 1 blend while showing no appreciable interface for a 1 :2 blend. The dotted lines indicate the theoretical end point values for spin diffusion in case of 1:1 (•) and 1:2 ( ⁇ ) blends.
- the inset shows the resonances from the double carbons (a, b). Spectrum of the crosslinked sample was collected on a film sample which was irradiated under visible light for 2 hours. The disappearance of the double bonds indicates complete crosslinking in the sample.
- Fig. 28A-28B depict nonwoven crosslinked tubes of gelatin methacrylamide (Fig. 28 A) prior to hydration and (Fig. 28B) in hydrated state. A 5 cm 14 mm tube is shown.
- Fig. 29A shows the diffusion profiles obtained from PFGNMR measurements for varying diffusion times are shown as a function of the magnetic field gradient.
- Figure 30A-30B provide a comparison of data between natural systems and electrospun fabrics produced in the lab.
- Fig. 30A shows the stress-strain behavior of human iliac artery, data from Roach M.R. and Burton A.L. (1957) Can. J. Biochem. Physiol. 35: 681, 1957.
- Fig. 30B shows the stress-strain behavior of crosslinked collagen and elastin fabrics produced by electrospinning. The mechanical behavior of the fabricated materials qualitatively mimics the behavior of natural artery. 5 DETAILED DESCRIPTION OF THE INVENTION
- Abbreviations used in the present application include the following: PEO, poly (ethylene oxide); PGA, polyglycolic acid; AME, acrylate modified elastin (or elastin mimetic); DOF, degree of functionalization; DCC, dicyclohexylcarbodiimide; DDG, 2,3-dichloro-5,6-dicyano- 1,4-benzoquinone; DMAP, N,N-dimethylaminopyridine; EY, eosin Y; FITC, fluorescein
- the arterial wall as representative of other tissues and organ systems can be considered in general terms as a fiber- reinforced composite material with associated mechanical properties largely a consequence of protein fiber networks.
- the local mechanical environment within the vessel wall 15 may in turn influence the functional responses of component cells.
- Biocompatibility refers to the interactions of living body tissues, compounds and fluids, including blood, etc. , with any implanted or contacting material (biomaterial).
- Biocompatible biomaterials are of great importance in any biomedical i0 application including, for example, in the implantation of vascular grafts and medical devices such as artificial organs, artificial heart valves, artificial joints, catheters and various other prosthetic devices into or on the body .
- Biomaterials with good biocompatibility do not trigger inflammatory reactions after implantation in or contact with human or animal tissue nor do they provide surfaces which are prone to thromboses.
- a functionalized protein is one which has, covalently bound to it, at least one moiety which mediates polymerization or crosslinkage with another moiety of the same chemical structure.
- the functionalized elastin mimetic protein, elastin, collagen or gelatin of the present invention comprise at least one polymerizable monomeric group, e.g., an acryloyloxy group, methacryl, dienyl, sorbyl, styryl, acrylamide, acrylonitrile, N-vinyl pyrrolidone, etc., which group is covalently attached to the protein and which modulates crosslinking between similarly functionalized proteins.
- photoirradiation mediates the crosslinking reaction in the presence of a suitable photoinitiator, under mild conditions of temperature and radical formation to minimize damage to the proteins.
- Functionalization of the protein is carried out so that the desirable mechanical and structural properties of the protein superstructure comprised of it are generally maintained. Conditions and initiators for crosslinking reactions are well known to the art.
- an elastin mimetic protein is one which has an amino acid sequence and secondary structure derived from native (naturally occurring) elastin.
- the elastin mimetic protein is recombinantly produced in Escherichia coli, and it is described in McMillan et al. (1999) Macromolecules 32: 3643-3648.
- This elastin mimetic protein contains 39 repeats of the amino acid sequence (Val-Pro-Gly-Val-Gly) 4 (Val-Pro-Gly-Lys- Gly) (SEQ ID NO:4). See also Huang et al. (2000) Macromolecules 33: 2989-2997 and McMillan et al. (2000) Macromolecules 33: 4809-4821. It is critical that it has elastomeric properties and tensile strength similar to those elastin when assembled into supramolecular structures such as fibers, fiber networks and nonwoven fabrics.
- Elastomeric proteins are widely distributed among a diverse range of animal species and tissues where they have evolved precise structures to perform specific biological functions. These proteins, which include for example, abductin [Cao et al. (1997) Curr. Biol. 1: R677-8] , tropoelastin [Gray et al. (1973) Nature 246: 461-6; Sandberg et al. (1981) N. Engl. J. Med. 304: 566-579; Urry et al. Ed., Birkhauser: Boston, 1997, pp 133-177] bysuss [Deming, T. J. (1999) Curr. Opin. Chem. Biol. 3: 100-5], silk [Hayashi et al. (1999) Int.
- elastomeric macromolecules must be crosslinked to form a network. Characteristically, elastic proteins combine elastomeric domains with domains that form covalent or noncovalent crosslinks. Thus, the size and properties of the elastic domains and the degree of crosslinking influence the elastic behavior
- Tensile strength is important in certain applications, and collagen and gelatin and crosslinked acrylate modified collagen improves the tensile strength of artificial fibers, fiber networks and fabrics and the like.
- Elastin which is derived from the soluble precursor tropoelastin, is widely distributed
- the elastin protein consists of repetitive glycine-rich hydrophobic elastomeric domains of variable length that alternate with alanine-rich, lysine-containing domains that form crosslinks [Sandberg et al. (1981). N. Engl. J. Med. 304: 566-579; Urry.et al. , Ed.; Birkhauser: Boston, 1997, pp 133-177; Sandberg et al. (1981). N. Engl. J. Med. 304: 566-579; Urry et al., Ed.; Birkhauser: Boston, 1997, pp 133-177]. Native elastin's intrinsic
- ⁇ 5 insolubility has largely limited its capacity to be purified and processed into forms suitable for biomedical or industrial applications. Recently, this limitation has been largely overcome, in part, by the structural characterization of the elastomeric domains. Specifically, comprehensive sequence analysis has revealed the presence of consensus tetra- (VPGG), penta- (VPGVG), and hexapeptides (APGVGV) repeat motifs [Gray et al. (1973) Nature 246: 461-6;
- elastin networks dominate low strain mechanical responses. Avoidance of artery wall fatigue and failure is dependent upon the resilience of elastin, which prevents the dissipation of transmitted pulsatile energy as heat. While elastin fibers are structurally complex and may contain glycoproteins and glycosaminoglycans , the physical properties of the network have been attributed primarily to the elastin protein component produced from the soluble precursor tropoelastin [Debelle et al. (1999) Internat. J. Biochem. Cell Biol. 31:261- 272]. Furthermore, extensive investigations by Urry and others [Urry et al. (1985) Biochem. Biophys. Res.
- Electrospinning is a third approach that has been recently utilized to generate protein fibers [Reneker et al. (1996) Nanotechnology 7: 216-223; Doshi et al. (1995) J. Electrostatics 35: 151-160].
- a polymer solution is subjected to an electric field that induces the accumulation of charge on the surface of a pendent drop.
- Mutual charge repulsion causes a force which directly opposes that 5 produced by surface tension.
- V start and V stop were proportionately related to the concentration of the peptide in solution and the corresponding viscosity (Fig. 1).
- V start was greater than 6.4 kV for all concentrations tested, and the splay was found to be unstable above 25 kV. Therefore, 18 kV was the chosen field strength for subsequent fiber formation investigations. Jet instability was observed at concentrations above 20 wt%, with an accompanying inability to form fibers.
- a systematic study of the influence on fiber morphology of the distance between the spinneret tip and the collecting plate revealed that 15 cm was an optimal distance for fiber formation.
- Fibers formed from a 5 wt% solution regardless of the mass flow rate, are short, fragmented and characterized by a triangular or spindle shaped beaded morphology (Fig. 2). Long uniform fibers were generated at solution concentrations above 10 wt% which corresponded to solution viscosities greater than 25 centipoise (Fig. 3). Fiber diameters range between 300 and 400 nm over all flow rates tested with little variation in morphology with the infrequent exception of fiber splitting at triangle-shaped bifurcation points . At a flow rate of 100 ⁇ l/min, it was estimated that 1500 meters of thin filament were produced per minute.
- Non- woven fabrics were formed from fibers generated from a 15 wt% of polypeptide 0 solution at a flow rate of 150 ⁇ l/ml (Fig. 7). As noted above, short time frame deposition studies had demonstrated that these conditions afforded the highest proportion of uniform, thin fibers with diameters of approximately 400 nm. Image analysis of the non-woven fabric revealed a unimodal distribution of fiber diameters with an observed average diameter of 450 nm (Fig. 8). The distribution of fiber orientation within this network followed a random ' 5 pattern of fiber deposition with consequent generation of an isotropic nonwoven fabric (Fig. 5 9). Uniaxial stress-strain properties were characterized in dry non-woven fabrics, and a representative data set is illustrated in Fig. 10. The ultimate tensile strength of the sample was 35 MPa and the material modulus 1.8 GPa. Hydration and peptide crosslinking modulate these properties.
- thermodynamic, and mechanical properties of the peptide polymer have led to the development of recombinant proteins that self-assemble into thermoreversible gels [Petka et al. (1998) Science 281:389-392], lyotropic smectic mesophases [Yu et al. (1997) Nature 389: 167-170], and lamellar crystallites [Krejchi et al. (1994) Science 265:1427-1432].
- the uniformity of macromolecular structure achieved has led to the development of recombinant proteins that self-assemble into thermoreversible gels [Petka et al. (1998) Science 281:389-392], lyotropic smectic mesophases [Yu et al. (1997) Nature 389: 167-170], and lamellar crystallites [Krejchi et al. (1994) Science 265:1427-1432].
- Elastin-mimetic protein fibers and fiber networks were produced by the electrospinning of an aqueous solution of a genetically engineered 81 kD peptide polymer based upon the
- Fibers were generated at ambient temperature and pressure with optimal fiber formation observed with use of an 18 kV electric field and a 15 cm distance between the spinneret and plate collector. High resolution SEM and TEM confirmed that fiber morphology was primarily influenced by solution concentration and mass flow rate. Characteristically, fiber
- elastin In its native form, elastin is present as a network of elastic fibers that are crosslinked through available lysine residues found in interspersed alanine-rich regions [Robins, S. P. (1982) Methods Biochem. Anal. 28: 329-379; Miyoshi et al. (1976) /. Biochem. (Tokyo) 79:
- Urry et al. have demonstrated the feasibility of generating tubular hydrogels by ⁇ -irradiation-mediated crosslinking [Urry et al. (1997) supra] and Welsh et al. have used glutaraldehyde to crosslink an elastin-mimetic protein film [Welsh, E. R. and
- Fig. 11 A The spectrum of the modified material expanded between 5.0 and 5.7 ppm is shown in the inset in Fig. 11 A. The spectrum clearly indicates the incorporation of the double bonds through peaks at 5.3 (H a ) and 5.6 ppm (H b ).
- Fig. 11B is the expanded version of the spectra, between 2.6 and 3.1 ppm.
- Acrylate modification results in about 0.25 ppm (H d ) downfield shift for the methylene protons alpha to the amino group (H c ). This shift can be used to directly calculate the degree of functionalization (DOF).
- DOF degree of functionalization
- the ratio of the integrated intensity of the 3 ppm peak to the sum of the integrated intensities of the 3 and 2.75 ppm peaks defines the DOF.
- IR spectroscopy can be used to evaluate DOF.
- the NH 2 band at 3500 cm-1 decreases with functionalization.
- the DOF can be varied by changing the molar reactant ratio of the methacryloyl anhydride to the amino groups in the peptide polymer.
- Fig. 12 illustrates the variation in the DOF that can be achieved, as demonstrated by changes in peak intensities in the H NMR spectrum.
- the 3 ppm peak is absent.
- the DOF can be varied from 33 % to 88 % by changing the feed ratio from 1 : 1 to 3 : 1.
- T t The inverse temperature transition (T t ) of elastin-mimetic and acrylate-modified analogues has been analyzed. Mutual compatibility of a polymer and a solvent has been extensively studied and is often critical for processing needs.
- Urry et. al. have shown that a family of protein polymers based on the VPGVG (SEQ ID NO:2) repeat undergo an inverse 5 temperature transition [Urry et al. (1985) Biopolymers 24: 2345-56].
- the proteins were found to undergo molecular assembly by protein folding with phase separation.
- poly(GVGVP) is miscible with water in all proportions below 25 °C, but on increasing the temperature above 25 °C, the solution becomes turbid with complete phase separation.
- 0 temperature-dependent turbidimetry measurements can be used to quantify the inverse transition temperature.
- T t 5 can be considered the T t .
- the data demonstrate that acrylate-modification causes a reduction in the inverse temperature transition with 88% conversion of the amino groups, producing a reduction in the transition temperature by about 50 °C (T t ⁇ 23 °C). This reduction is consistent with the T t -based hydrophobicity scale developed by Urry et. al. [Urry et al. (1985) Biopolymers 24: 2345-56]. Their investigations established that an increase in the
- the crosslinking of the acrylate moiety is mediated through a photoinitiator.
- the 10 mechanism for photocrosslinking has been extensively reviewed [Eaton, D. F. (1986) Advances in Photochemistry 13: 427-487]. Because fiber spinning is conducted from aqueous solutions, water-soluble photoinitiators are desirable.
- Irgacure 2959 is l-[4- hydroxyethoxy)-pheny]-2-hydroxy-2-methyl-l-propane-l-one; Ciba Geigy), both of whichhave 15 been used as photoinitiators in water-based systems [Van Den Bulcke et al. (2000) Biomacromolecules 1: 31; Cruise et al. (1998) Biotechnol. Bioeng. 57: 655-65]. While both photoinitiators were tested for crosslinking efficiency, the reported mechanical results are for the EY-based systems. Other photoinitiators which function under mild conditions of temperature and without producing a level of free radicals which lead to protein damage can be used, and the selection of light wavelength and temperature for a particular combination of wavelength and functional group are well understood in the art.
- Figs. 14 and 15 show SEM micrographs of the fibers produced from 10 and 15 wt% solutions at a flow rate of 50 ⁇ l/min, as described in Example 4. In both cases, long uniform fibers were produced. In fibers spun from the 10 wt% solution, average diameter ranged between 300 - 500 nm with occasional triangle shaped bifurcation points noted. In contrast, fibers spun from the 15 wt% solution were exhibited a flat or ribbon type morphology with the absence of triangular bifurcation points. In comparison to our previous investigation of unmodified elastin-mimetic fibers, neither acrylate-modification nor the addition of photoinitiator to the spinning solution had any appreciable effect on fiber morphology.
- Fig. 17 shows representative stress-strain curves of the two samples .
- the uncrosslinked material elastin methacrylamide
- the crosslinked sample had a modulus of 0.7 ⁇ 0.15 GPa and a tensile strength of 16.2 + 6.3 MPa
- the crosslinked sample had a modulus of 1.8 + 0.4 GPa and a tensile strength of 43.3 ⁇ 5.2 MPa.
- crosslinking enhanced both Young's modulus and tensile strength with a concomitant decrease in the strain to failure from 3.9 + 0.2 % to 2.1 ⁇ 0.35 % .
- Fig. 18 shows the comparative stress-strain behavior of dry and hydrated crosslinked samples of AME(65). Clearly rubber elastic behavior ensues subsequent to hydration.
- the hydrated sample had an average modulus of 0.45 + 0.08 MPa and a strain to failure of 105 ⁇ 8 % .
- the degree of crosslinking estimated from ideal rubber elasticity theory compares well with that obtained from solid-state NMR.
- Collagen is a biodegradable, biocompatible, and non-immunogenic structural protein, which makes it a suitable compound for a variety of biomedical applications.
- Examples include collagen use in cosmetic and urological surgery as an injectable compound for tissue augmentation, in orthopedic surgery as an implantable matrix to promote bone growth, and in plastic and general surgery as a topical agent for the treatment of both chronic non-healing wounds and burn injuries or as a template for tissue regeneration.
- type I collagen is composed of two ⁇ l(I) chains and one ⁇ 2(I) chain, each slightly more than 1000 amino acids long, that are organized as a triple helix and stabilized primarily by hydrogen bonds.
- a single molecule of type I collagen has a molecular mass of 285 kD, a width of " 14 A, and a length of ⁇ 3000 A.
- collagen has been predominantly used after processing into a dry powder or slurry, a hydrogel after solution phase crosslinking, or as a porous matrix with or without the addition of other components after freeze-drying.
- type I collagen molecules form 5 fibrillar elements, twenty to several hundred nanometers in diameter that are organized into protein networks of varying architecture.
- collagen fiber networks act to resist high strain deformation and in the process transmit forces, dissipate energy, and prevent premature tissue mechanical failure.
- These fiber networks constitute the principle structural elements of a variety of acellular bioprosthetic tissue substitutes, such as porcine heart valves
- tissue derived matrices including porcine subintestinal submucosa and bovine pericardium.
- the versatility of collagen as a scaffold for tissue engineering applications is significantly enhanced when used as a native protein network. To date, attempts to reformulate tissue extracted native collagen into protein fiber networks and fabrics have been limited.
- PEO is non-toxic, chemically stable in acidic solution, and when of sufficient molecular weight is capable of forming electrospun fibers .
- fibers could not be formed from a 1-2 wt% pure collagen in aqueous solution, but were observed after the addition of PEO.
- High resolution SEM demonstrated unique morphological features as a function of the weight
- the dipolar magnetization transfer method depends on creating a magnetization gradient across the sample and then monitoring the time it takes for spin equilibration to occur following the creation of the gradient. This equilibration time will depend upon the domain sizes in the system and the spin diffusion coefficients associated with each phase. If the diffusion coefficients of different regions and the dimensionality of the diffusion process are known a priori, then the domain sizes in the system can be extracted by fitting a simulated diffusion profile to the experimental data. The simulated profile can be obtained by numerically solving the diffusion equation with appropriate initial and boundary conditions. It is also clear that if diffusivities are isotropic, then only the minimum domain distances will be probed since the shortest path for the establishment of spin equilibration lies along this direction (D. L.
- the domain distances that can be observed using spin diffusion range from about 2 nm to 100 nm.
- the upper bound for the observable domain distance will depend upon the time in which it is possible to observe the magnetization polarization. This is governed by the spin lattice relaxation of protons in the sample.
- the maximum domain distance observable there are many multiphase polymer systems that exhibit domains of the order that can be investigated by the spin diffusion technique. For example, long periods in semicrystalline polymers and domain sizes in many block copolymers fall well within the range of detection by spin diffusion [K. J. Packer et al. (1984) J. Polym. Sci. : Polym. Phys. 22: 589; Kimura et al (1992) Polymer 33: 493; Cai et al. (1993) Polymer 34: 267].
- Collagen fibers were spun and cross linked into fibers using collagen dissolved in fluorinated solvent or dissolved in a water-fluorinated solvent mixture. Although collagen fibers could not be produced from 1-2 wt% solutions in water, either changing the temperature or altering the solvent system can produce pure collagen fibers . By increasing the temperature to 36 °C formation of collagen fibers were noted. Fluorinated alcohol/water mixtures can serve as alternate solvents systems to produce collagen fibers. For example production of collagen fibers in the 300-800 nm diameter range could be achieved from spinning 10-15 wt% of collagen in such fluorinated solvents.
- the solvent compositions used were (a) 10 mole% trifluoroethanol (TFE)/90 mole% water and (b) 10 mole % hexafluoroisopropanol (HFIP)/90 mole% water.
- TFE trifluoroethanol
- HFIP hexafluoroisopropanol
- Collagen spinning can also be effected from combinations of water with other fluorinated alcohols.
- the magnetization gradient is usually realized by using an appropriate selection sequence.
- a simple filter based on spin-spin relaxation can be used to selectively retain the magnetization of the more mobile phase. For example, consider a blend of two components A and B with disparately different T 2 's. If A has a T 2 of 100 ⁇ s and B has a T 2 of 1 ms, then by applying a T 2 filter of 700 ⁇ s, one can destroy the magnetization in A and selectively retain the magnetization in B, thereby creating a magnetization gradient.
- Fig. 21 shows the CP/MAS/TOSS and DP/MAS spectra of collagen, PEO and an electrospun fabric of 1 :2 collagen/PEO.
- the CP spectrum of the collagen/PEO fabric appears to be a simple superposition of the CP spectra of collagen and PEO in that it shows the resonances from both collagen and PEO.
- the DP spectra typically discriminate against the more rigid regions in the sample.
- the DP spectrum of collagen indicates that it is very rigid at the measuring temperature (24 °C).
- the reported glass transition of dry collagen is approximately 125 °C rendering collagen rigid at room temperature.
- the DP spectrum of PEO indicates that PEO is highly mobile at room temperature (T , PEO - 65 °C).
- Fig. 22A shows the H spectra of an electrospun 1:2 collagen- PEO fabric before and after the application of the dipolar filter.
- the spectrum acquired before the application of the filter is a superposition of a broad (rigid) and a narrow (mobile) component.
- the spectrum acquired after the application of the filter shows only the narrow component indicating that the filter has destroyed the magnetization associated with the rigid regions.
- a CP/MAS sequence was appended to the spin diffusion sequence as described in the experimental section.
- the 13 C CP/MAS spectra are shown in Fig. 22B.
- the spin diffusion data for 1:1 and 1:2 fabric blends are shown in Fig. 23.
- the inset in Figure 7 shows the initial time data. From the inset it is clear that the magnetization in the source phase contacts the sink phase slower in the 1:1 blend than in the 1:2 blend (the initial portion of the curve for the 1:1 blend is sigmoidal while it is linear for the 1:2 blend). This is indicative of the presence of an interface in the 1:1 blend while there is very little or no interface in the 1:2 blend.
- the formation of an interface in the case of the 1:1 blend is not surprising since the potential exists for hydrogen bonding between the ether oxygen of the PEO and protons of the amino group in collagen.
- the presence of associative interactions has known to produce phase mixing in polymer blends . Thus , mere visual inspection of the initial 5 time data suggests that mechanically stronger fabrics could be produced from the 1 : 1 blend due to the presence of an interface.
- the dotted lines in the figure represent the theoretical (expected) end value of spin diffusion. As expected the theoretical end value for the 1 :2 blend (0.74) is greater than the 1 : 1
- Non- woven fabrics were formed from collagen/PEO fibers generated from a 2 wt% of type I collagen-PEO solution at a flow rate of lOO ⁇ L/mL and uniaxial stress-strain properties characterized in the dry state.
- a pure PEO fabric sample had the lowest tensile strength of 90 KPa and a modulus of 7 MPa. The tensile strength and modulus of a 1 :2 collagen-PEO blend
- Type I collagen-PEO fibers and non-woven fiber networks were produced by the electtospinning of a weak acid solution of lyophilized collagen purified from rat tail tendon.
- Fibers were generated at ambient temperature and pressure with optimal fiber formation observed with use of an 18 kV electric field and a 15-cm distance between the spinneret and 5 plate collector .
- Fiber morphology was influenced by solution viscosity , conductivity , and flow rate.
- highly uniform fibers with a diameter range of 100 - 150 nm were produced from a 2 wt% solution of collagen-PEO (1:1 weight ratio, 34 mM NaCl) at a flow rate of lOO ⁇ L/min.
- the ultimate tensile strength of the resulting non-woven fabric was 370 KPa with an elastic modulus of 12 MPa.
- Efforts to process collagen into man-made fibers have been limited, and generally approaches to date have been confined to wet spinning methodologies.
- Wet spinning involves the extrusion of a protein solution through a spinneret into an acid-salt coagulating bath, which usually contains aqueous ammonium sulfate, acetic acid, isopropanol, or acetone. Further treatments in ethanol and acetone solutions are often required for fiber dehydration.
- Limitations of this approach include the use of biologically toxic solvent systems that preclude the fabrication in real time of hybrid protein-cell constructs, as well as conditions which likely induce significant conformational changes in native protein structure, including protein denaturation.
- wet spinning is largely confined to the generation of fibers that range from tens to hundreds of microns in diameter .
- the process outlined herein provides a convenient, non-toxic, non-denaturing approach for the generation collagen-containing nanofibers and non-woven fabrics that have applications in medical and veterinary prostheses, artificial organs, wound healing and tissue engineering, and as hemostatic agents.
- Fig. 24 shows the H NMR spectra of gelatin and acrylate modified gelatin in D 2 O recorded at 45 °C. Incorporation of double bonds in the system can be inferred from the
- DOF degree of functionalization
- Fig. 25 shows the stress-strain data for crosslinked gelatin methacrylamide films with 15 varying photoinitiator concentration. Going from the standard to medium photoinitiator 5 concentration provides a moderate increase in modulus while significantly decreasing the strain to failure. However, going from medium to high photoinitiator concentrations decreased the modulus slightly. Hubell et. al have previously reported that the photopolymerization process can be adversely affected by increasing the concentration of TEA. Increased TEA concentrations are believed to lead to more radicals being generated, and these radicals in tarn
- Fig. 26 shows the ultimate tensile strength, modulus, and strain to failure of hydrated samples as a function of irradiation time. The ultimate tensile strength and the modulus increased with
- E 3 p R T/M c
- E the modulus
- p the density
- R the gas constant
- rthe temperature the average molecular weight between crosslinks.
- M c can be calculated from the measured modulus (from the tensile testing experiments) and this quantity is inversely proportional to the degree of crosslinking.
- degree of crosslinking is directly proportional to the modulus of the material.
- modulus measurements can also be used to provide a rough estimate of the degree of crosslinking.
- Natural elastin has a modulus of abut 0.9 to about 1.1 MP*.
- Electrospinning was also used to produce acrylate modified fibers and fabric networks of crosslinked gelatin.
- the description of the apparatus has been provided in detail in the previous section.
- the field strength, deposition distance and flow rate were kept constant at 18 kV, 10 cm, and 30 ⁇ L/min respectively.
- 18-kV field strength and 10-cm deposition distance seemed to provide the best fiber splays, while increasing the flow rate beyond 30 ⁇ L/min lead to the formation of droplets.
- Fibers formed from both unmodified gelatin and acrylate modified gelatin using the aforementioned parameters were analyzed with scanning electron microscopy to delineate their morphology. The concentration of gelatin in solution was found to be the major variable affecting fiber morphology.
- the fibers formed from 25 wt% unmodified gelatin in water suggest that increasing concentration will yield non-beaded fibers obviating the need for the addition of NaCl or any other salt.
- the fiber diameters in case of the acrylate modified samples were in the 500 to 1500nm diameter range. The significant increase in the fiber diameter in the acrylated fibers is due to bead formation.
- Electrospinning for extended periods of time will yield a nonwoven fabric network that consists of nano-diameter fibers.
- a rotating mandrel instead of a plate, a nonwoven tube of crosslinked gelatin can be produced.
- Fig. 29A shows a nonwoven tube of crosslinked gelatin, 5 cm in length and 14 mm in diameter. The diameter of the tabes can be varied by increasing or decreasing the size of the mandrel.
- Fig. 29B also shows the tabe in the hydrated state (i.e., immersed in water). The tabe retains its shape even after prolonged immersion in water, indicating that the crosslinking reaction has proceeded to completion.
- the electrospinning method and the chemistry outlined one can begin to form constructs, which may have applications in the medical field.
- PFGNMR pulsed field gradient NMR spectroscopy
- Fig. 29B the normalized intensity is plotted as a function of a parameter 2 that is given by
- Monoclonal or polyclonal antibodies preferably monoclonal, specifically reacting with a particular protein of interest may be made by methods known in the art. See, e.g. , Harlow and Lane (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratories; Goding
- Standard techniques for cloning, DNA isolation, amplification and purification, for enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like, and various separation techniques are those known and commonly employed by those skilled in the art.
- a number of standard techniques are described in Sambrook et al. (1989) Molecular Cloning, Second Edition, Cold Spring Harbor Laboratory, Plainview, New York; Maniatis et al. (1982) Molecular Cloning, Cold Spring Harbor Laboratory, Plainview, New York; Wu (ed.) (1993) Meth. Enzymol. 218, Part I; Wu (ed.) (1979) Meth Enzymol. 68; Wu et al. (eds.) (1983) Meth.
- a concatameric synthetic gene of 3000 base pairs encodes a repetitive polypeptide comprising 39 repeats of the elastm-mimetic sequence.
- the protein polymer was expressed from recombinant plasmid pRAMl in E. coli strain BLR(DE3) under the regulatory control of a lac promoter with isopropyl ⁇ - 5 thiogalactopyranoside induction. It was purified to a high yield (64 mg/L) by reversible, temperature-induced precipitation from the cell lysate.
- the sequence of the protein polymer ' has been confirmed by automated Edman degradation and MALDI-TOF mass spectroscopy of site-specific proteolytic cleavage fragments . Structural analysis of this recombinant protein has also included SDS PAGE, as well as *H and 13 C NMR [McMillan et al. (1999) Macromolecules
- Methacryloyl anhydride, eosin Y (EY, 5 wt% in water), triethanolamine (TEA) and 1- vinyl-2-pyrrolidinone (VP) were obtained from Aldrich (Milwaukee, WI) and were used as received.
- a UV sensitive radical photoinitiator l-(4-(2-hydroxyethoxy)phenyl)-2-hydroxy-2- ,0 methyl-1-propan-l-one (Irgacure 2959) was kindly supplied by Ciba Speciality Chemicals (Tarrytown, NY). Dialysis was conducted using Spectra/pro membrane (MWCO 6000-8000) obtained from VWR Scientific (West Chester, PA).
- PEO Polyethylene oxide
- Dawley rats weighing between 250 to 350 grams using a protocol similar to that described by
- tendon fibers were extracted from rat tails using a wire stripper, immersed in 10 mM HCl (pH 2.0; 10 fibers per 100 mL), and stirred for 4 hours at room temperature. The soluble component was separated from the insoluble portion after
- Lyophilized collagen was obtained by dialyzing the collagen solution overnight against distilled, deionized water (18 M ⁇ » cm, Continental), followed by lyophilization. Prior to use, lyophilized collagen was dissolved in 10 mM HCl at room temperature for 1 hour. The identity and purity of the collagen samples was confirmed by polyacrylamide gel electrophoresis.
- Gelatin Type A - Porcine Skin, 300 Bloom; product #G-2500
- 2,2,2- trifluororethanol purchased from Sigma Chemical Inc. , St. Louis, MO.
- Methacryloyl anhydride (94%), Eosin-Y 5wt. % in water, l-vinyl-2-pyrrolidinone (99 + %), and triethanolamine (98%) were purchased from Aldrich Chemical Inc. , Milwaukee, WI.
- Phosphate buffer used was an aqueous solution of sodium dihydrogen phosphate , monohydrate (J.T.Baker Inc. , Phillipsburg, NJ) and disodium hydrogen phosphate (Fisher Scientific, Fair Lawn, NJ).
- Example 3 Fiber Spinning Elastin-mimetic peptide polymers were spun into fibers using an electrospinning technique, as detailed elsewhere. Briefly, peptide polymer solutions (10 - 15 wt%) were prepared in ultrafiltered grade, distilled, deionized water (18 M ⁇ ' cm, Continental) by mixing for 12 hrs at 4°C. With the aid of a syringe pump (Harvard Apparatus, Inc. , Holliston, MA), the solution was extruded at ambient temperatare and pressure and at a defined flow rate through a positively charged metal blunt tipped needle (22Gxl.5 inch). The needle was connected to a 1 mL syringe using TygonTM (trademark of San Diego Plastics, Inc.
- V start and V stop defined as the electric potential necessary to initiate or terminate jet formation, respectively were determined for different concentrations of elastm-mimetic polypeptide solutions.
- Fabric samples were produced by electrospinning solutions for extended periods of time.
- the apparatus was modified to include a rotating mandrel to produce fabric samples.
- the fabric samples were collected on an aluminum foil wrapped around the grounded mandrel placed at a prescribed horizontal distance with respect to the charged tip of the needle.
- Collagen-PEO solutions (1-2 wt %) were prepared in 10 mM HCl (pH 2.0) by mixing for 2 hours at ambient temperature . With the aid of a syringe pump (Harvard Apparatus , Inc . ) , the solution was extruded at ambient temperature and pressure and at a defined flow rate through a positively charged metal blunt tipped needle (22G x 1.5 inch). Fibers were collected on a grounded aluminum plate located below the tip of the needle. A high voltage, low current power supply (ES30P/DDPM, Gamma High Voltage Research, Inc) was utilized to establish the electric potential gradient, which was varied between 0 and 30 kV, as indicated.
- E30P/DDPM Gamma High Voltage Research, Inc
- DOF degree of functionalization
- Electrospinning was used to spin fibers of AME from aqueous solutions. Solution concentration, flow rate and operating voltage were found to be the critical parameters 0 affecting the spinning process. The details of the technique and optimization of process parameters to yield smooth nanofibers have been discussed in detail in an earlier report. [Huang et al. (2000) Macromolecules 33, 2989].
- a solution of 10-15 wt% AME(65) polymer in ddH.20 was prepared with the addition of 5 wt% (of the protein polymer content) of l triethanolamine, as free radical crosslinker. For example, to each 100 mgs of protein polymer, 5 5 mgs of triethanolamine or approximately 50 ⁇ L of the stock EY/TEA/VP solution was added.
- a field strength of 18 kV was chosen for fiber formation and the distance between the syringe tip and the collecting plate was fixed at 15 cm. The flow rate was 50 ⁇ l/min.
- a stock solution of EY photoinitiator was prepared as 10 mM EY, 225 mM TEA, and 37 mM VP in water. Irgacure 2959 was directly added to the prepared protein solution.
- acrylate modified gelatin a 5-weight % solution of gelatin was made in lOmM phosphate buffer solution, pH 7.5. To this solution a four times excess of methacryloyl anhydride (in relation to target amino acid residues) was added to the solution. The reaction was then stirred at 40 °C for 4 hours. The solution was then dialyzed using a Spectra/Por membrane (MWCO: 6-8,000) against 60 volumes of ddH 2 0 at 40°C for 48hrs with constant changes in the dialyzing solution. The solution was then lyophilized and the dialyzate was stored at -30 °C.
- the gelatin electrospinning apparatus consisted of a syringe pump (Harvard Apparatus), a syringe, an 18 gauge blunt end needle (Popper and Sons, Inc.), a grounded rotating metallic 14mm O.D. mandrel (for production of tabes), a grounded 10cm by 10 cm aluminum covered plate (for flat fabric production), an electric mandrel rotor, a Dyna-Lume "dyna-light” #240- 380, and a high voltage source (Gamma High Voltage, HV power supply, c.f. , Figure 1(a)).
- Solutions of gelatin and acrylated gelatin were prepared in concentrations from 10wt% to 25wt% in ddU 2 0 along with 222 ⁇ L of the high concentration photo initiator solution.
- the syringe containing the acrylated gelatin/photo initiator solution was shielded during spinning with an opaque tape to prevent premature crosslinking.
- the needle was heated using a heating lamp to avoid gelation in the needle and to maintain uniform flow rate.
- the temperature profile across the syringe and the needle was obtained with a type K thermocouple. Temperature readings were obtained across four points (labeled T 1 through T 4 in the figure) in the syringe. The profiles were measured after steady state had been achieved.
- the temperature in the needle could be adjusted to desired levels.
- the temperatare was maintained between 45 and 55 °C.
- the applied field of 18kV and deposition distance of 10 cm were kept constant for all runs.
- a flow rate of 30 ⁇ L/min was maintained during elecfrospinning, because flow rates in excess of 30 ⁇ L/min produced droplets.
- the fibers on deposition were exposed to light throughout the spinning process and for an additional two hours after fiber spinning had ceased.
- a layer of polyethylene oxide (MW ⁇ 900 kDa) was deposited on the aluminum foil to achieve a lOO ⁇ m thick covering.
- the acrylated gelatin fibers were then deposited on top of the PEO layer. Deposition time varied depending on the volume of material to be spun.
- Example 6 Image capture of non-woven fabric samples and analysis of fiber diameter and orientation distribution
- Fabrics were generated by electrospinning at a 150 ⁇ l/min from a 15 wt% solution of elastin-mimetic peptide polymer. Specimens were placed directly on a mirror and imaged using a directional lighting arrangement where light is coUimated using an "on-axis" system comprised of both a diffuser and a beam-splitter. Light passes through the sample and is reflected vertically off the mirror surface back to a CCD camera. Specular reflections from fiber surfaces do not reach the camera. Thus, fibers, regardless of their position within the fabric, merely block the light, appear dark, and are in focus. Captured images underwent segmentation or "threshholding" in order to isolate individual fibers from background.
- fiber orientation is characterized by utilizing a chord-tracking algorithm, which tracks fixed small segments of individual fibers. Details of these automated image analysis techniques, as applied to fiber networks in the form of non- woven fabrics, are provided elsewhere [Pourdeyhimi et al (1999) Textile Res. J. 69: 233-236; PourdeyMmi et al (2001) Textile Res. J. 71: 157-164]. Analysis of fiber diameter and orientation distribution was based upon a minimum of 10 image fields obtained from at least two separate samples.
- a miniature materials tester Minimat 2000 (Rheometric Scientific, Piscataway, NJ) was used to determine the tensile properties of the unmodified and the modified elastin fabrics .
- the machine was used in the tensile deformation mode with a 20N load cell and a strain rate of 1 mm/min.
- Fabric samples (10mm X 1.5 mm X 0.05 mm) were used as test specimens with a gauge length of 8mm. For each sample, eight specimens were tested and average modulus and tensile strength values were determined.
- Standard cross polarization (CP) pulse sequence was employed under conditions of magic angle spinning (MAS). A spinning speed of 5 kHz was employed.
- a TOSS sequence was used in conjunction with CP to provide a spectrum free of spinning sidebands [Dixon, W. T. (1982) J. Chem. Phys. 11, 1800; Dixon et al. (1982) J. Magn. Reson. 49, 341].
- Standard cross polarization (CP) pulse sequence was employed under conditions of magic angle spinning (MAS). A spinning speed of 5 kHz was employed. A TOSS sequence was used in conjunction with CP to provide a spectrum free of spinning sidebands. 20 A 4.5- ⁇ s ! H 90° pulse, a 1-ms contact time, a 9- ⁇ s I3 C 180° pulse, and a 3-sec recycle delay were employed with accumulation of 5000 to 16000 scans for signal averaging.
- a CP sequence was appended to the dipolar filter sequence.
- a 3 -sec recycle delay, a 4.5- ⁇ s H 90° pulse, and a 1-ms contact time were used.
- the experiment was conducted under conditions of MAS with a spinning speed of 5 kHz and 10,000 scans were acquired for signal averaging.
- Temperature-dependent turbidimetry measurements were recorded in an Ultrospec 3000 UV/visible spectrophotometer equipped with a programmable Peltier Cell and temperatare control unit from Amersham Pharmacia Biotech, Inc. (Piscataway, NJ). Inverse temperatare transitions of elastin-mimetic polypentapeptide and its acrylate modified analogs were monitored in ddK 2 0 solution (concentration of 0.5 - 0.7 mg/ml) at 280 nm.
- TEM transmission electron microscopy
- JEOL 1210 TEM was operated at 70 kV voltage. Fiber samples were deposited onto silicon chips and carbon coated grids for scanning and transmission EM stadies, respectively. Samples containing silicon chips were subsequently mounted onto aluminum specimen stubs with silver paste, degassed for 30 minutes, and coated with a 1 nm chromium (Cr) ultrathin film using a Denton DV-602 Turbo Magnetron Sputter System.
- Cr chromium
- Visible light irradiation was performed using a DynaLume quartz halogen illuminator equipped with a heat shield obtained from Scientific Instruments. Ultraviolet irradiation was performed with an UVP 8-watt handheld model (model UVL-18) operating at 365 nm.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Textile Engineering (AREA)
- Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Artificial Filaments (AREA)
- Nonwoven Fabrics (AREA)
Abstract
Description
Claims
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01928716A EP1274469A2 (en) | 2000-04-20 | 2001-04-20 | Native protein mimetic fibers, fiber networks and fabrics for medical use |
| US10/258,207 US20040110439A1 (en) | 2001-04-20 | 2001-04-20 | Native protein mimetic fibers, fiber networks and fabrics for medical use |
| JP2001578015A JP2004525268A (en) | 2000-04-20 | 2001-04-20 | Native protein mimic fibers, fiber networks and fabrics for medical applications |
| AU2001255544A AU2001255544A1 (en) | 2000-04-20 | 2001-04-20 | Native protein mimetic fibers, fiber networks and fabrics for medical use |
| CA002406862A CA2406862A1 (en) | 2000-04-20 | 2001-04-20 | Native protein mimetic fibers, fiber networks and fabrics for medical use |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19879200P | 2000-04-20 | 2000-04-20 | |
| US60/198,792 | 2000-04-20 | ||
| US22182800P | 2000-07-28 | 2000-07-28 | |
| US60/221,828 | 2000-07-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001080921A2 true WO2001080921A2 (en) | 2001-11-01 |
| WO2001080921A3 WO2001080921A3 (en) | 2002-02-28 |
Family
ID=26894159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/012918 Ceased WO2001080921A2 (en) | 2000-04-20 | 2001-04-20 | Native protein mimetic fibers, fiber networks and fabrics for medical use |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1274469A2 (en) |
| JP (1) | JP2004525268A (en) |
| AU (1) | AU2001255544A1 (en) |
| CA (1) | CA2406862A1 (en) |
| WO (1) | WO2001080921A2 (en) |
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002032397A2 (en) | 2000-10-18 | 2002-04-25 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessing in drug delivery and cell encapsulation |
| WO2004030712A1 (en) * | 2002-10-01 | 2004-04-15 | Johnson & Johnson Medical Limited | Controlled release therapeutic wound dressings |
| EP1422242A1 (en) * | 2002-11-22 | 2004-05-26 | Emory University | Plastic and elastic protein copolymers |
| JP2004231633A (en) * | 2002-11-22 | 2004-08-19 | Emory Univ | Plastic and elastic protein copolymer |
| US6936298B2 (en) | 2000-04-13 | 2005-08-30 | Emory University | Antithrombogenic membrane mimetic compositions and methods |
| GB2393724B (en) * | 2002-10-01 | 2006-04-12 | Johnson & Johnson Medical Ltd | Controlled release therapeutic wound dressings |
| JP2006512154A (en) * | 2002-12-30 | 2006-04-13 | ボストン サイエンティフィック リミテッド | Engineering-designed framework for promoting cell growth |
| WO2006041130A1 (en) * | 2004-10-14 | 2006-04-20 | National University Corporation Hokkaido University | Gel for zymography |
| WO2006099315A3 (en) * | 2005-03-11 | 2006-12-28 | Univ Wake Forest Health Sciences | Electrospun cell matrices |
| EP1698356A4 (en) * | 2003-12-26 | 2007-03-14 | Cardio Inc | DECELLULARIZED FABRIC AND METHOD OF PREPARING THE SAME |
| US7244830B2 (en) | 2001-01-12 | 2007-07-17 | Emory University | Glycopolymers and free radical polymerization methods |
| US7374774B2 (en) | 1999-08-31 | 2008-05-20 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed material made by simultaneously electroprocessing a natural protein polymer and two synthetic polymers |
| WO2008093342A2 (en) | 2007-02-01 | 2008-08-07 | Technion Research & Development Foundation Ltd. | Albumin fibers and fabrics and methods of generating and using same |
| EP1982735A1 (en) | 2000-11-17 | 2008-10-22 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen |
| US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| US7713544B2 (en) | 2000-07-28 | 2010-05-11 | Emory University | Biological component comprising artificial membrane |
| AU2003236491B2 (en) * | 2002-11-22 | 2010-05-13 | Emory University | Plastic and elastic protein copolymers |
| US7824672B2 (en) | 2004-03-26 | 2010-11-02 | Emory University | Method for coating living cells |
| US7833978B2 (en) | 2004-02-20 | 2010-11-16 | Emory University | Thrombomodulin derivatives and conjugates |
| US7842780B2 (en) | 2003-01-07 | 2010-11-30 | Trustees Of Tufts College | Silk fibroin materials and use thereof |
| EP2295630A1 (en) * | 2009-09-11 | 2011-03-16 | Basf Se | Method for producing coated protein fibres |
| US7993738B2 (en) * | 2004-11-30 | 2011-08-09 | The Regents Of The University Of Michigan | Modified porous materials and method of forming the same |
| US8101717B2 (en) | 2006-11-13 | 2012-01-24 | The University Of Sydney | Use of tropoelastin for repair or restoration of tissue |
| US8491457B2 (en) | 2005-03-11 | 2013-07-23 | Wake Forest University Health Services | Tissue engineered blood vessels |
| US8728463B2 (en) | 2005-03-11 | 2014-05-20 | Wake Forest University Health Science | Production of tissue engineered digits and limbs |
| US8846624B2 (en) | 2006-09-11 | 2014-09-30 | Emory University | Modified protein polymers |
| US9248015B2 (en) | 2005-03-11 | 2016-02-02 | Wake Forest University Health Services | Production of tissue engineered heart valves |
| CN105326581A (en) * | 2015-09-29 | 2016-02-17 | 中国科学院金属研究所 | Method of preparing polyethylene glycol and protein fiber combined artificial cardiac valve |
| US10092679B2 (en) | 2013-10-18 | 2018-10-09 | Wake Forest University Health Sciences | Laminous vascular constructs combining cell sheet engineering and electrospinning technologies |
| EP3460115A4 (en) * | 2016-03-16 | 2020-07-29 | Kabushiki Kaisha Toshiba | FIBER RAIL AND METHOD FOR PRODUCING IT |
| CN111529759A (en) * | 2020-04-23 | 2020-08-14 | 东华大学 | A macroporous bone tissue engineering scaffold capable of continuously releasing inorganic active components and preparation method thereof |
| US10801140B2 (en) | 2016-03-16 | 2020-10-13 | Kabushiki Kaisha Toshiba | Fiber sheet and method for manufacturing same |
| CN111961164A (en) * | 2020-09-18 | 2020-11-20 | 宜宾惠美纤维新材料股份有限公司 | Cashmere protein and preparation method of cashmere protein fiber |
| CN113230461A (en) * | 2021-05-06 | 2021-08-10 | 东华大学 | Micro-nanofiber-hydrogel tissue engineering ureter and preparation method thereof |
| US20220280691A1 (en) * | 2019-07-31 | 2022-09-08 | Freie Universität Berlin | Photocurable composition |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007044648B4 (en) * | 2007-09-18 | 2020-11-26 | Carl Freudenberg Kg | Bioresorbable gelatin non-woven fabric |
| WO2022172929A1 (en) * | 2021-02-09 | 2022-08-18 | 信越化学工業株式会社 | Gelatine-containing device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474851A (en) * | 1981-10-02 | 1984-10-02 | The University Of Alabama In Birmingham | Elastomeric composite material comprising a polypeptide |
| EP0302892B1 (en) * | 1986-04-17 | 1994-07-13 | The Uab Research Foundation | Segmented polypeptide bioeleastomers to modulate elastic modulus |
| FR2655048A1 (en) * | 1989-11-27 | 1991-05-31 | Inst Nat Sante Rech Med | PROCESS FOR OBTAINING BIOACTIVE COPOLYMERS BY GRAFTING VINYL PATTERNS AND RESULTING GRAFT COPOLYMERS. |
| WO1998034563A1 (en) * | 1997-02-07 | 1998-08-13 | Sisters Of Providence In Oregon | Method for using tropoelastin and for producing tropoelastin biomaterials |
| US6458386B1 (en) * | 1997-06-03 | 2002-10-01 | Innogenetics N.V. | Medicaments based on polymers composed of methacrylamide-modified gelatin |
| EP1022031B1 (en) * | 1999-01-21 | 2005-03-23 | Nipro Corporation | Suturable adhesion-preventing membrane |
-
2001
- 2001-04-20 AU AU2001255544A patent/AU2001255544A1/en not_active Abandoned
- 2001-04-20 CA CA002406862A patent/CA2406862A1/en not_active Abandoned
- 2001-04-20 WO PCT/US2001/012918 patent/WO2001080921A2/en not_active Ceased
- 2001-04-20 EP EP01928716A patent/EP1274469A2/en not_active Withdrawn
- 2001-04-20 JP JP2001578015A patent/JP2004525268A/en not_active Withdrawn
Cited By (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
| US7374774B2 (en) | 1999-08-31 | 2008-05-20 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed material made by simultaneously electroprocessing a natural protein polymer and two synthetic polymers |
| US6936298B2 (en) | 2000-04-13 | 2005-08-30 | Emory University | Antithrombogenic membrane mimetic compositions and methods |
| US7713544B2 (en) | 2000-07-28 | 2010-05-11 | Emory University | Biological component comprising artificial membrane |
| WO2002032397A2 (en) | 2000-10-18 | 2002-04-25 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessing in drug delivery and cell encapsulation |
| EP1982735A1 (en) | 2000-11-17 | 2008-10-22 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen |
| US7244830B2 (en) | 2001-01-12 | 2007-07-17 | Emory University | Glycopolymers and free radical polymerization methods |
| GB2393724B (en) * | 2002-10-01 | 2006-04-12 | Johnson & Johnson Medical Ltd | Controlled release therapeutic wound dressings |
| WO2004030712A1 (en) * | 2002-10-01 | 2004-04-15 | Johnson & Johnson Medical Limited | Controlled release therapeutic wound dressings |
| AU2003236491B2 (en) * | 2002-11-22 | 2010-05-13 | Emory University | Plastic and elastic protein copolymers |
| EP1422242A1 (en) * | 2002-11-22 | 2004-05-26 | Emory University | Plastic and elastic protein copolymers |
| JP2004231633A (en) * | 2002-11-22 | 2004-08-19 | Emory Univ | Plastic and elastic protein copolymer |
| JP2006512154A (en) * | 2002-12-30 | 2006-04-13 | ボストン サイエンティフィック リミテッド | Engineering-designed framework for promoting cell growth |
| US9993527B2 (en) | 2003-01-07 | 2018-06-12 | Trustees Of Tufts College | Silk fibroin materials and use thereof |
| US8361617B2 (en) | 2003-01-07 | 2013-01-29 | Trustees Of Tufts College | Silk fibroin materials and use thereof |
| US11110148B2 (en) | 2003-01-07 | 2021-09-07 | Trustees Of Tufts College | Silk fibroin materials and use thereof |
| US7842780B2 (en) | 2003-01-07 | 2010-11-30 | Trustees Of Tufts College | Silk fibroin materials and use thereof |
| US9132197B2 (en) | 2003-01-07 | 2015-09-15 | Massachusetts Institute Of Technology | Silk fibroin materials and use thereof |
| EP1698356A4 (en) * | 2003-12-26 | 2007-03-14 | Cardio Inc | DECELLULARIZED FABRIC AND METHOD OF PREPARING THE SAME |
| US7833978B2 (en) | 2004-02-20 | 2010-11-16 | Emory University | Thrombomodulin derivatives and conjugates |
| US7824672B2 (en) | 2004-03-26 | 2010-11-02 | Emory University | Method for coating living cells |
| WO2006041130A1 (en) * | 2004-10-14 | 2006-04-20 | National University Corporation Hokkaido University | Gel for zymography |
| US7993738B2 (en) * | 2004-11-30 | 2011-08-09 | The Regents Of The University Of Michigan | Modified porous materials and method of forming the same |
| US9801713B2 (en) | 2005-03-11 | 2017-10-31 | Wake Forest University Health | Production of tissue engineered heart valves |
| US9163331B2 (en) | 2005-03-11 | 2015-10-20 | Wake Forest University Health Sciences | Electrospun cell matrices |
| US8491457B2 (en) | 2005-03-11 | 2013-07-23 | Wake Forest University Health Services | Tissue engineered blood vessels |
| WO2006099315A3 (en) * | 2005-03-11 | 2006-12-28 | Univ Wake Forest Health Sciences | Electrospun cell matrices |
| US9248015B2 (en) | 2005-03-11 | 2016-02-02 | Wake Forest University Health Services | Production of tissue engineered heart valves |
| US8728463B2 (en) | 2005-03-11 | 2014-05-20 | Wake Forest University Health Science | Production of tissue engineered digits and limbs |
| US9039782B2 (en) | 2005-03-11 | 2015-05-26 | Wake Forest University Health Sciences | Production of tissue engineered digits and limbs |
| US8846624B2 (en) | 2006-09-11 | 2014-09-30 | Emory University | Modified protein polymers |
| US8101717B2 (en) | 2006-11-13 | 2012-01-24 | The University Of Sydney | Use of tropoelastin for repair or restoration of tissue |
| WO2008093342A3 (en) * | 2007-02-01 | 2009-07-23 | Technion Res & Dev Foundation | Albumin fibers and fabrics and methods of generating and using same |
| US8546333B2 (en) | 2007-02-01 | 2013-10-01 | Technion Research & Development Foundation Limited | Albumin fibers and fabrics and methods of generating and using same |
| US8551948B2 (en) | 2007-02-01 | 2013-10-08 | Technion Research & Development Foundation Limited | Albumin fibers and fabrics and methods of generating and using same |
| WO2008093342A2 (en) | 2007-02-01 | 2008-08-07 | Technion Research & Development Foundation Ltd. | Albumin fibers and fabrics and methods of generating and using same |
| EP2478924A1 (en) * | 2007-02-01 | 2012-07-25 | Technion Research & Development Foundation | Albumin fibers and fabrics and methods of generating and using same |
| EP2295630A1 (en) * | 2009-09-11 | 2011-03-16 | Basf Se | Method for producing coated protein fibres |
| US10092679B2 (en) | 2013-10-18 | 2018-10-09 | Wake Forest University Health Sciences | Laminous vascular constructs combining cell sheet engineering and electrospinning technologies |
| US10751447B2 (en) | 2013-10-18 | 2020-08-25 | Wake Forest University Health Sciences | Laminous vascular constructs combining cell sheet engineering and electrospinning technologies |
| CN105326581A (en) * | 2015-09-29 | 2016-02-17 | 中国科学院金属研究所 | Method of preparing polyethylene glycol and protein fiber combined artificial cardiac valve |
| US11421360B2 (en) | 2016-03-16 | 2022-08-23 | Kabushiki Kaisha Toshiba | Fiber sheet and method for manufacturing same |
| EP3460115A4 (en) * | 2016-03-16 | 2020-07-29 | Kabushiki Kaisha Toshiba | FIBER RAIL AND METHOD FOR PRODUCING IT |
| US10801140B2 (en) | 2016-03-16 | 2020-10-13 | Kabushiki Kaisha Toshiba | Fiber sheet and method for manufacturing same |
| US20220280691A1 (en) * | 2019-07-31 | 2022-09-08 | Freie Universität Berlin | Photocurable composition |
| CN111529759A (en) * | 2020-04-23 | 2020-08-14 | 东华大学 | A macroporous bone tissue engineering scaffold capable of continuously releasing inorganic active components and preparation method thereof |
| CN111961164A (en) * | 2020-09-18 | 2020-11-20 | 宜宾惠美纤维新材料股份有限公司 | Cashmere protein and preparation method of cashmere protein fiber |
| CN111961164B (en) * | 2020-09-18 | 2022-04-05 | 宜宾惠美纤维新材料股份有限公司 | Cashmere protein and preparation method of cashmere protein fiber |
| CN113230461B (en) * | 2021-05-06 | 2022-02-15 | 东华大学 | Micro-nanofiber-hydrogel tissue engineering ureter and preparation method thereof |
| CN113230461A (en) * | 2021-05-06 | 2021-08-10 | 东华大学 | Micro-nanofiber-hydrogel tissue engineering ureter and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1274469A2 (en) | 2003-01-15 |
| WO2001080921A3 (en) | 2002-02-28 |
| AU2001255544A1 (en) | 2001-11-07 |
| JP2004525268A (en) | 2004-08-19 |
| CA2406862A1 (en) | 2001-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040110439A1 (en) | Native protein mimetic fibers, fiber networks and fabrics for medical use | |
| EP1274469A2 (en) | Native protein mimetic fibers, fiber networks and fabrics for medical use | |
| Zhang et al. | Dehydrothermally crosslinked collagen/hydroxyapatite composite for enhanced in vivo bone repair | |
| US5171273A (en) | Synthetic collagen orthopaedic structures such as grafts, tendons and other structures | |
| EP2125050B1 (en) | Albumin fibers and fabrics and methods of generating and using same | |
| Nguyen et al. | Fabrication and characterization of cross-linked gelatin electro-spun nano-fibers | |
| EP0850074B1 (en) | Biomaterials for preventing post-surgical adhesions comprised of hyaluronic acid derivatives | |
| AU677789B2 (en) | Biocompatible polymer conjugates | |
| Fullana et al. | Electrospun collagen and its applications in regenerative medicine | |
| CN102458493B (en) | New collagen-based materials and preparation method thereof | |
| CN105555832B (en) | Bioelastomer and its application | |
| Jalaja et al. | Fabrication of cationized gelatin nanofibers by electrospinning for tissue regeneration | |
| WO2012070680A1 (en) | Non-fibrillar collagen molded body and method for producing same | |
| Dehghan-Manshadi et al. | The influence of elastomeric polyurethane type and ratio on the physicochemical properties of electrospun polyurethane/silk fibroin hybrid nanofibers as potential scaffolds for soft and hard tissue engineering | |
| JP4417909B2 (en) | Elastin molded body and production method thereof | |
| KR20220150308A (en) | Tissue Engineering Scaffolds | |
| CN113209384B (en) | Pelvic floor patch for gynecology and preparation method thereof | |
| CN120535580B (en) | Preparation method and application of polypeptide gel with mechanical contraction characteristics and scar inhibition | |
| BAHRIA et al. | Discussion of unconventional Electrospinning of collagen I | |
| Ján | The effect of various conditions of dehydrothermal crosslinking on the mechanical and structural properties of electrospun collagen nanofibers | |
| Wnek | Electrospun collagen and its applications in regenerative medicine | |
| KR20250158802A (en) | Multifilament collagen fiber bundle having a structure similar to tendon and method for producing the same | |
| Arnoult | A Novel Benign Solution for Collagen Processing | |
| Nam | 4.2. Biological properties of EN and Co Pho gels | |
| Zeugolis | Reconstituted collagen fibres for tissue engineering applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 578015 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2406862 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001928716 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2001928716 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10258207 Country of ref document: US |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2001928716 Country of ref document: EP |